Potential of human fetal chorionic stem cells for the treatment of Osteogenesis imperfecta

Jones, Gemma N., Moschidou, Dafni, Abdulrazzak, Hassan, Kalirai, Bhalraj Singh, Vanleene, Maximilien, Osatis, Suchaya, Shefelbine, Sandra J., Horwood, Nicole J., Marenzana, Massimo, De Coppi, Paolo, Bassett, J. H. Duncan, Williams, Graham R., Fisk, Nicholas M. and Guillot, Pascale V. (2014) Potential of human fetal chorionic stem cells for the treatment of Osteogenesis imperfecta. Stem Cells and Development, 23 3: 262-276. doi:10.1089/scd.2013.0132

Author Jones, Gemma N.
Moschidou, Dafni
Abdulrazzak, Hassan
Kalirai, Bhalraj Singh
Vanleene, Maximilien
Osatis, Suchaya
Shefelbine, Sandra J.
Horwood, Nicole J.
Marenzana, Massimo
De Coppi, Paolo
Bassett, J. H. Duncan
Williams, Graham R.
Fisk, Nicholas M.
Guillot, Pascale V.
Title Potential of human fetal chorionic stem cells for the treatment of Osteogenesis imperfecta
Journal name Stem Cells and Development   Check publisher's open access policy
ISSN 1547-3287
Publication date 2014-02-01
Sub-type Article (original research)
DOI 10.1089/scd.2013.0132
Open Access Status
Volume 23
Issue 3
Start page 262
End page 276
Total pages 15
Place of publication New Rochelle, NY, United States
Publisher Mary Ann Liebert
Collection year 2015
Language eng
Abstract Osteogenesis imperfecta (OI) is a genetic bone pathology with prenatal onset, characterized by brittle bones in response to abnormal collagen composition. There is presently no cure for OI. We previously showed that human first trimester fetal blood mesenchymal stem cells (MSCs) transplanted into a murine OI model (oim mice) improved the phenotype. However, the clinical use of fetal MSC is constrained by their limited number and low availability. In contrast, human fetal early chorionic stem cells (e-CSC) can be used without ethical restrictions and isolated in high numbers from the placenta during ongoing pregnancy. Here, we show that intraperitoneal injection of e-CSC in oim neonates reduced fractures, increased bone ductility and bone volume (BV), increased the numbers of hypertrophic chondrocytes, and upregulated endogenous genes involved in endochondral and intramembranous ossification. Exogenous cells preferentially homed to long bone epiphyses, expressed osteoblast genes, and produced collagen COL1A2. Together, our data suggest that exogenous cells decrease bone brittleness and BV by directly differentiating to osteoblasts and indirectly stimulating host chondrogenesis and osteogenesis. In conclusion, the placenta is a practical source of stem cells for the treatment of OI.
Q-Index Code C1
Q-Index Status Confirmed Code
Institutional Status UQ

Document type: Journal Article
Sub-type: Article (original research)
Collections: UQ Centre for Clinical Research Publications
Official 2015 Collection
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 7 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 9 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Tue, 18 Feb 2014, 00:22:49 EST by System User on behalf of UQ Centre for Clinical Research